JP2021528400A5 - - Google Patents

Info

Publication number
JP2021528400A5
JP2021528400A5 JP2020570158A JP2020570158A JP2021528400A5 JP 2021528400 A5 JP2021528400 A5 JP 2021528400A5 JP 2020570158 A JP2020570158 A JP 2020570158A JP 2020570158 A JP2020570158 A JP 2020570158A JP 2021528400 A5 JP2021528400 A5 JP 2021528400A5
Authority
JP
Japan
Prior art keywords
cancer
antibody
patient
grem1
gremlin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020570158A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021528400A (ja
JP7565219B2 (ja
Filing date
Publication date
Priority claimed from GBGB1809946.5A external-priority patent/GB201809946D0/en
Priority claimed from GBGB1815694.3A external-priority patent/GB201815694D0/en
Application filed filed Critical
Priority claimed from PCT/GB2019/051699 external-priority patent/WO2019243801A1/en
Publication of JP2021528400A publication Critical patent/JP2021528400A/ja
Publication of JP2021528400A5 publication Critical patent/JP2021528400A5/ja
Application granted granted Critical
Publication of JP7565219B2 publication Critical patent/JP7565219B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020570158A 2018-06-18 2019-06-18 がんを予防及び治療するためのgremlin-1アンタゴニスト Active JP7565219B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1809946.5A GB201809946D0 (en) 2018-06-18 2018-06-18 Prevention and treatment of cancer
GB1809946.5 2018-06-18
GBGB1815694.3A GB201815694D0 (en) 2018-09-26 2018-09-26 Prevention and treatment of cancer
GB1815694.3 2018-09-26
PCT/GB2019/051699 WO2019243801A1 (en) 2018-06-18 2019-06-18 Gremlin-1 antagonist for the prevention and treatment of cancer

Publications (3)

Publication Number Publication Date
JP2021528400A JP2021528400A (ja) 2021-10-21
JP2021528400A5 true JP2021528400A5 (cg-RX-API-DMAC7.html) 2022-06-10
JP7565219B2 JP7565219B2 (ja) 2024-10-10

Family

ID=67107908

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020570158A Active JP7565219B2 (ja) 2018-06-18 2019-06-18 がんを予防及び治療するためのgremlin-1アンタゴニスト

Country Status (22)

Country Link
US (1) US12162934B2 (cg-RX-API-DMAC7.html)
EP (1) EP3806898B1 (cg-RX-API-DMAC7.html)
JP (1) JP7565219B2 (cg-RX-API-DMAC7.html)
KR (1) KR102957598B1 (cg-RX-API-DMAC7.html)
CN (1) CN112533632A (cg-RX-API-DMAC7.html)
AU (1) AU2019289176B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020025661A2 (cg-RX-API-DMAC7.html)
CA (1) CA3102743A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020003249A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020015923A2 (cg-RX-API-DMAC7.html)
DK (1) DK3806898T3 (cg-RX-API-DMAC7.html)
ES (1) ES3054944T3 (cg-RX-API-DMAC7.html)
FI (1) FI3806898T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251604T1 (cg-RX-API-DMAC7.html)
IL (1) IL279347B2 (cg-RX-API-DMAC7.html)
LT (1) LT3806898T (cg-RX-API-DMAC7.html)
MX (1) MX2020013808A (cg-RX-API-DMAC7.html)
PL (1) PL3806898T3 (cg-RX-API-DMAC7.html)
PT (1) PT3806898T (cg-RX-API-DMAC7.html)
SG (1) SG11202012312UA (cg-RX-API-DMAC7.html)
SI (1) SI3806898T1 (cg-RX-API-DMAC7.html)
WO (1) WO2019243801A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
AU2019289176B2 (en) 2018-06-18 2026-02-19 Adelaide university Gremlin-1 antagonist for the prevention and treatment of cancer
EP4232475A1 (en) 2020-10-20 2023-08-30 Kantonsspital St. Gallen Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof
AU2022207030A1 (en) * 2021-01-18 2023-08-24 Suzhou Transcenta Therapeutics Co., Ltd. Novel anti-gremlin1 antibodies
KR20230156936A (ko) * 2021-03-11 2023-11-15 상하이 지아오통 대학 그렘린1 길항제를 사용하여 질환을 치료하는 방법
GB202205203D0 (en) 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
GB202205200D0 (en) 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
AU2023258146A1 (en) 2022-04-20 2024-09-05 Kantonsspital St. Gallen Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
WO2024026505A2 (en) * 2022-07-29 2024-02-01 Amit Patel Disruption of telocyte activity
KR20250169623A (ko) * 2023-04-13 2025-12-03 쑤저우 트랜스센타 테라퓨틱스 컴퍼니 리미티드 암 치료를 위한 grem1 길항제를 수반하는 조합 요법
CN118304412B (zh) * 2024-03-26 2026-05-01 中山大学附属第七医院(深圳) 一种特异性阻断acvr1c与grem1结合的多肽及其应用
WO2026027660A1 (en) 2024-08-02 2026-02-05 UCB Biopharma SRL Formulations of anti-gremlin-1 antibodies

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
ES2201097T3 (es) 1994-01-31 2004-03-16 Trustees Of Boston University Bibliotecas de anticuerpos policlonales.
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
EP1357828A2 (en) 2001-01-12 2003-11-05 University of Medicine and Dentistry of New Jersey Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
WO2004051268A1 (en) 2002-12-03 2004-06-17 Celltech R & D Limited Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
PT1644412E (pt) 2003-07-01 2015-12-23 Ucb Biopharma Sprl Fragmentos de anticorpos fab modificados
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
WO2005023993A2 (en) 2003-09-09 2005-03-17 Integrigen, Inc. Methods and compositions for generation of germline human antibody genes
EP1571159A1 (en) 2004-03-04 2005-09-07 Bayerische Julius-Maximilians-Universität Würzburg Mutein of a bone morphogenetic protein and use thereof
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
US20090203041A1 (en) 2006-04-21 2009-08-13 Wei Shi Bmp4 inhibitors
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
US8383349B2 (en) * 2007-03-16 2013-02-26 The Board Of Trustees Of The Leland Stanford Junior University Bone morphogenetic protein antagonist and uses thereof
EP2535350B1 (en) 2007-09-26 2018-01-24 UCB Biopharma SPRL Dual specificity antibody fusions
WO2013137686A1 (ko) 2012-03-15 2013-09-19 서울대학교 산학협력단 그렘린-1에 대한 항체
BR112015021979A2 (pt) 2013-03-14 2017-08-29 Regeneron Pharma Anticorpos humanos para grem1
WO2016014904A1 (en) * 2014-07-24 2016-01-28 Beta Pharma, Inc. 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
CN111170998B (zh) * 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
AU2015360360B2 (en) * 2014-12-11 2020-06-25 Beta Pharma (Shanghai) Co., Ltd. Substituted 2-anilinopyrimidine derivatives as EGFR modulators
GB201621635D0 (en) * 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
SG11201911859QA (en) * 2017-06-16 2020-01-30 Beta Pharma Inc Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
WO2019148161A1 (en) * 2018-01-29 2019-08-01 Beta Pharma, Inc. 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
AU2019289176B2 (en) 2018-06-18 2026-02-19 Adelaide university Gremlin-1 antagonist for the prevention and treatment of cancer

Similar Documents

Publication Publication Date Title
KR102495426B1 (ko) 항her3 항체-약물 콘주게이트
JP2021514664A5 (cg-RX-API-DMAC7.html)
JP2020528750A5 (cg-RX-API-DMAC7.html)
JP2015517300A5 (cg-RX-API-DMAC7.html)
JP7249696B2 (ja) 抗cldn抗体並びにその医薬組成物および検出方法
FI3806898T3 (fi) Gremlin-1-antagonisti käytettäväksi syövän hoidossa
UA119036C2 (uk) Терапія раку, яка включає антитіло проти клаудину 18.2
JP2021528047A5 (cg-RX-API-DMAC7.html)
CA2798778A1 (en) Anti-human trop-2 antibody having anti-tumor activity in vivo
MX2012011234A (es) Anticuerpos contra csf-1r.
ES2759329T3 (es) Anticuerpos contra la anfirregulina, composiciones que los comprenden y usos de los mismos
JP2017512759A5 (cg-RX-API-DMAC7.html)
JP2020505075A5 (cg-RX-API-DMAC7.html)
JP2024538148A5 (cg-RX-API-DMAC7.html)
WO2015076425A1 (ja) 新規モノクローナル抗体
EP2561356A1 (en) MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES
AU2015280436A1 (en) Antibodies that bind LGR4
JP2020537490A (ja) モノクローナル抗体抗fgfr4
JP2021512652A5 (cg-RX-API-DMAC7.html)
JP2025511940A5 (cg-RX-API-DMAC7.html)
JP2012144498A (ja) 抗腫瘍剤
JP7438560B2 (ja) Smoタンパク質の特異的エピトープ、これを認知する抗体及びこれを含む組成物
JP2021524032A (ja) Gasp−1顆粒を標的とする結合性タンパク質及びキメラ抗原受容体t細胞並びにそれらの使用
US12091453B2 (en) Epitope specific to SMO protein, antibody recognizing same, and composition comprising same
JP2024502670A5 (cg-RX-API-DMAC7.html)